Immunotherapy in kidney cancer: The past, present, and future

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Purpose of review Kidney cancer, in particular clear cell renal cell carcinoma (ccRCC) has long been considered to be sensitive to immunotherapies. With the recent breakthroughs in immunotherapy for solid tumors and the recent approval of the first immune checkpoint inhibitor for ccRCC, we are reviewing the history of immunotherapy in kidney cancer, describing its current state and look into the future of a rapidly evolving landscape in immunotherapy for kidney cancer. Recent findings Systemic treatment options over the past decade have been dominated by targeted therapies inhibiting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. With the approval of the immune checkpoint inhibitor nivolumab, a new era of potential combination therapies is about to shape the treatment landscape for kidney cancer. These include other immune checkpoint inhibitors (e.g., anti-CTLA4), modifiers of the tumor microenvironment (VEGF pathway, T cell agonists (anti-41BB and Ox40 antibodies), and novel vaccination strategies). Summary With the development of more effective combination immunotherapies, we will witness significant changes in the treatment landscape for kidney cancer over the next few years. Combination immunotherapies are expected to become the first line treatment option in kidney cancer.

Original languageEnglish (US)
Pages (from-to)543-547
Number of pages5
JournalCurrent Opinion in Urology
Volume26
Issue number6
DOIs
StatePublished - Oct 1 2016

Fingerprint

Kidney Neoplasms
Immunotherapy
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Therapeutics
Tumor Microenvironment
Sirolimus
Vaccination
History
T-Lymphocytes
Antibodies
Neoplasms

Keywords

  • Adoptive therapy
  • Immune checkpoints
  • Kidney cancer
  • Vaccines

ASJC Scopus subject areas

  • Urology

Cite this

Immunotherapy in kidney cancer : The past, present, and future. / Hammers, Hans.

In: Current Opinion in Urology, Vol. 26, No. 6, 01.10.2016, p. 543-547.

Research output: Contribution to journalReview article

@article{6cb6cd17020f45c9b4e563efc4e09ee7,
title = "Immunotherapy in kidney cancer: The past, present, and future",
abstract = "Purpose of review Kidney cancer, in particular clear cell renal cell carcinoma (ccRCC) has long been considered to be sensitive to immunotherapies. With the recent breakthroughs in immunotherapy for solid tumors and the recent approval of the first immune checkpoint inhibitor for ccRCC, we are reviewing the history of immunotherapy in kidney cancer, describing its current state and look into the future of a rapidly evolving landscape in immunotherapy for kidney cancer. Recent findings Systemic treatment options over the past decade have been dominated by targeted therapies inhibiting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. With the approval of the immune checkpoint inhibitor nivolumab, a new era of potential combination therapies is about to shape the treatment landscape for kidney cancer. These include other immune checkpoint inhibitors (e.g., anti-CTLA4), modifiers of the tumor microenvironment (VEGF pathway, T cell agonists (anti-41BB and Ox40 antibodies), and novel vaccination strategies). Summary With the development of more effective combination immunotherapies, we will witness significant changes in the treatment landscape for kidney cancer over the next few years. Combination immunotherapies are expected to become the first line treatment option in kidney cancer.",
keywords = "Adoptive therapy, Immune checkpoints, Kidney cancer, Vaccines",
author = "Hans Hammers",
year = "2016",
month = "10",
day = "1",
doi = "10.1097/MOU.0000000000000338",
language = "English (US)",
volume = "26",
pages = "543--547",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Immunotherapy in kidney cancer

T2 - The past, present, and future

AU - Hammers, Hans

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Purpose of review Kidney cancer, in particular clear cell renal cell carcinoma (ccRCC) has long been considered to be sensitive to immunotherapies. With the recent breakthroughs in immunotherapy for solid tumors and the recent approval of the first immune checkpoint inhibitor for ccRCC, we are reviewing the history of immunotherapy in kidney cancer, describing its current state and look into the future of a rapidly evolving landscape in immunotherapy for kidney cancer. Recent findings Systemic treatment options over the past decade have been dominated by targeted therapies inhibiting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. With the approval of the immune checkpoint inhibitor nivolumab, a new era of potential combination therapies is about to shape the treatment landscape for kidney cancer. These include other immune checkpoint inhibitors (e.g., anti-CTLA4), modifiers of the tumor microenvironment (VEGF pathway, T cell agonists (anti-41BB and Ox40 antibodies), and novel vaccination strategies). Summary With the development of more effective combination immunotherapies, we will witness significant changes in the treatment landscape for kidney cancer over the next few years. Combination immunotherapies are expected to become the first line treatment option in kidney cancer.

AB - Purpose of review Kidney cancer, in particular clear cell renal cell carcinoma (ccRCC) has long been considered to be sensitive to immunotherapies. With the recent breakthroughs in immunotherapy for solid tumors and the recent approval of the first immune checkpoint inhibitor for ccRCC, we are reviewing the history of immunotherapy in kidney cancer, describing its current state and look into the future of a rapidly evolving landscape in immunotherapy for kidney cancer. Recent findings Systemic treatment options over the past decade have been dominated by targeted therapies inhibiting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. With the approval of the immune checkpoint inhibitor nivolumab, a new era of potential combination therapies is about to shape the treatment landscape for kidney cancer. These include other immune checkpoint inhibitors (e.g., anti-CTLA4), modifiers of the tumor microenvironment (VEGF pathway, T cell agonists (anti-41BB and Ox40 antibodies), and novel vaccination strategies). Summary With the development of more effective combination immunotherapies, we will witness significant changes in the treatment landscape for kidney cancer over the next few years. Combination immunotherapies are expected to become the first line treatment option in kidney cancer.

KW - Adoptive therapy

KW - Immune checkpoints

KW - Kidney cancer

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84983086689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983086689&partnerID=8YFLogxK

U2 - 10.1097/MOU.0000000000000338

DO - 10.1097/MOU.0000000000000338

M3 - Review article

C2 - 27533501

AN - SCOPUS:84983086689

VL - 26

SP - 543

EP - 547

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 6

ER -